Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Circadin in mild to moderate Alzheimer's disease
NCT00940589Phase 2Completed
- Sponsor
- Neurim Pharmaceuticals
- Start
- Sep 2009
- Primary completion
- Feb 2013
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial in Alzheimer's disease (AD) comparing Circadin with Placebo (2 arms). Primary endpoint: Alzheimer's Disease Assessment Scale - Cognitive Subscale at 24 weeks. Started Sep 2009; status: completed.
02
Drugs
melatonin
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT00940589.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00940589.